Prosecution Insights
Last updated: November 20, 2026
Application No. 18/556,488

THE IMMUNOMODULATORY LIGAND B7-1 MEDIATES SYNAPTIC REMODELING BY P75NTR

Final Rejection §102§103
Filed
Oct 20, 2023
Priority
Apr 22, 2021 — provisional 63/178,163 +2 more
Examiner
SULLIVAN, DENNIS JOHN
Art Unit
1642
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Columbia University
OA Round
2 (Final)
58%
Grant Probability
Moderate
3-4
OA Rounds
7m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 58% of resolved cases
58%
Career Allowance Rate
69 granted / 119 resolved
-2.0% vs TC avg
Strong +48% interview lift
Without
With
+48.3%
Interview Lift
resolved cases with interview
Typical timeline
3y 8m
Avg Prosecution
45 currently pending
Career history
171
Total Applications
across all art units

Statute-Specific Performance

§101
6.6%
-33.4% vs TC avg
§103
41.9%
+1.9% vs TC avg
§102
4.0%
-36.0% vs TC avg
§112
27.1%
-12.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 119 resolved cases

Office Action

§102 §103
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Priority Applicant’s claim for the benefit of a prior-filed application under 35 U.S.C. 119(e) or under 35 U.S.C. 120, 121, 365(c), or 386(c) is acknowledged. Claims 1-17 have an effective filing date of 22APR2021. Status of Claims Claims 1-17 are currently pending and presented for examination on the merits. Claims 18-37 are canceled. Objections Withdrawn The objection to claims 13 and 17 are withdrawn in view of Applicant’s amendments to the claim. Rejections Withdrawn The rejection filed under 35 U.S.C. 112(b) is withdrawn in view of Applicant’s amendments to claims. Rejections Maintained Claim Rejections - 35 USC § 102 The rejection of claims 15-17 under 35 U.S.C. 102(a)(1) as being anticipated by Kannarkat et al (The Role of Innate and Adaptive Immunity in Parkinson's Disease, J Parkinsons Dis. 2013 ; 3(4): 493–514) is withdrawn in view of the claim amendments. Rejections Maintained Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claims 1-2, and 6-7 are rejected under 35 U.S.C. 103 as being unpatentable over Morano et al (Structural and Functional Investigations Into B7-1:NGFR, The Journal of Immunology, Vol 202, Iss. 1_Supplemental, May 2019, IDS 10/20/2023). In regard to claims 1 and 6-7, Morano et al teaches a method of using CTLA4 to compete with Nerve Growth Factor Receptor (NGFR, TNFSFR16) for binding to B7-1 [Abstract]. Morano et al teaches B7-1 binding CD28 induces T-cell activation [Abstract]. Morano et al further teaches that B7-1 binding CTLA4 reduces naïve T-cell activation [Abstract]. Morano et al further teaches p75 neurotrophin receptor competing with CTLA4 for B7-1 binding [Abstract]. Applicant states in the specifications, “p75 neurotrophin receptor (p75NTR, NGFR, TNFRSF16, CD271)” [Pg. 17, Specifications]. One of ordinary skill, before the effective filing date, would have been motivated to use Morano’s method of using CTLA4 to compete with p75 neurotrophin receptor for binding to B7-1. It would have been prima facie obvious to use Morano’s method for a method comprising incubating CTLA4 with B7-1 and p75 neurotrophin receptor and measuring CTLA4 reducing B7-1 binding to p75 neurotrophin receptor, because Morano teaches B7-1 binding CTLA4 reduces naïve T-cell activation, motivated because Morano teaches this is a way to reduce T-cell activation after B7-1 binds p75 neurotrophin receptor. In regard to claim 2, Morano teaches CTLA4 that is on naïve T-cell cell surface [Abstract]. Claims 1-7 are rejected under 35 U.S.C. 103 as being unpatentable over Morano et al (Structural and Functional Investigations Into B7-1:NGFR, The Journal of Immunology, Vol 202, Iss. 1_Supplemental, May 2019, IDS 10/20/2023) as applied to claims 1-2, and 6-7 above, and further in view of Brennan et al (US 20190202889 A1, IDS 10/20/2023). The teachings of Morano et al are discusses above. Morano et al does not specifically teach soluble forms of B7-1. However, this deficiency is made up in the teachings of Brennan et al. Applicant states in the specification, “B7-1 (CD80)” [Pg. 4, Specification]. In regard to claim 3, Brennan et al teaches soluble forms of CD80 [0006]. One of ordinary skill, before the effective filing date, would be motivate to combine Morano’s method of using CTLA4 to compete with p75 neurotrophin receptor for binding to B7-1, with Brennan’s method of use soluble B7-1 (CD80), fused to a Fc fragment, and bound to beads. The idea of combining them flows logically from their having been individually taught in the prior art (MPEP 2144.06). Combining prior art elements according to known methods to yield predictable results is an exemplary rationale for a prima facie case of obviousness. MPEP2143. It would have been prima facie obvious to combine Morano and Brennan’s methods for a method comprising incubating CTLA4 with B7-1 and p75 neurotrophin receptor and measuring CTLA4 reducing B7-1 binding to p75 neurotrophin receptor. Furthermore, for the B7-1 to be in a soluble form, fused to a Fc fragment and bound to beads, because Morano teaches this is a way to reduce T-cell activation after B7-1 binds p75 neurotrophin receptor and Brennan teaches this is used in treatments of diseases. In regard to claim 4, Brennan et al teaches CD80 fused to IgG1 Fc [0184]. In regard to claim 5, Brennan et al teaches the CD80-Fc bound to magnetic protein-A beads [0184]. Claims 8 and 9 are rejected under 35 U.S.C. 103 as being unpatentable over Morano et al (Structural and Functional Investigations Into B7-1:NGFR, The Journal of Immunology, Vol 202, Iss. 1_Supplemental, May 2019, IDS 10/20/2023) as applied to claims 1-2, and 6-7 above, and further in view of Huxley et al (High-Affinity Small Molecule Inhibitors of T Cell Costimulation: Compounds for Immunotherpy, Chem. & Bio, Vol. 11, pgs. 1651-1658, Dec. 2004, IDS 10/20/2023). The teachings of Morano et al are discussed above. Morano et al does not specifically teach agents that reduce binding of B7-1 and CD28 or CTLA-4. However, this deficiency is made up in the teachings of Huxley et al. In regard to claim 8, Huxley et al teaches using CTLA-4Ig to block CD28 engagement of CD80 [Right column, 2nd paragraph, pg. 1651]. Huxley further teaches measuring the interactions by substituting a mouse immunoglobulin Fab fragment for the sCD80-Fab fusion protein [Right column, 2nd paragraph, pg. 1656]. One of ordinary skill, before the effective filing date, would be motivate to combine Morano’s method of using CTLA4 to compete with p75 neurotrophin receptor for binding to B7-1, with Huxley’s method of using CTLA-4Ig to block CD28 engagement of CD80 and measuring the blocking agents reduction in binding of B7-1 to CD28. The idea of combining them flows logically from their having been individually taught in the prior art (MPEP 2144.06). Combining prior art elements according to known methods to yield predictable results is an exemplary rationale for a prima facie case of obviousness. MPEP2143. It would have been prima facie obvious to combine Morano and Huxley’s methods for a method measuring CTLA4 reducing B7-1 binding to CD28, because Morano teaches this is a way to reduce T-cell activation and Huxley teaches reducing inflammatory disease. In regard to claim 9, Huxley et al teaches compound 1 that does not significantly reduce B7-1 binding to CD28 [Figure 2]. Claims 10-14, and 17 are rejected under 35 U.S.C. 103 as being unpatentable over Morano et al (Structural and Functional Investigations Into B7-1:NGFR, The Journal of Immunology, Vol 202, Iss. 1_Supplemental, May 2019, IDS 10/20/2023) and Huxley et al (High-Affinity Small Molecule Inhibitors of T Cell Costimulation: Compounds for Immunotherpy, Chem. & Bio, Vol. 11, pgs. 1651-1658, Dec. 2004, IDS 10/20/2023) as applied to claims 1-2, and 6-9 above, and further in view of Patnaik et al (Signaling via the p75 neurotrophin receptor facilitates amyloid-B-induced dendritic spine pathology, Scientific Reports, 10:13322, pgs. 1-14, 2020, IDS 10/20/2023). The teachings of Morano et al and Huxley et al are discussed above. Morano et al does not specifically teach measuring synaptic puncta density. However, this deficiency is made up in the teachings of Patnaik et al. In regard to claims 10 and 12, Patnaik et al teaches measuring synaptic puncta density of neurons that express p75 neurotrophin receptor [1st paragraph, pg. 4]. One of ordinary skill, before the effective filing date, would be motivate to combine Morano’s method of using CTLA4 to compete with p75 neurotrophin receptor for binding to B7-1, with Huxley’s method of using CTLA-4Ig to block CD28 engagement of CD80 and measuring the blocking agents reduction in binding of B7-1 to CD28, with Patnaik’s method of measuring synaptic puncta density of neurons that express p75 neurotrophin receptor. The idea of combining them flows logically from their having been individually taught in the prior art (MPEP 2144.06). Combining prior art elements according to known methods to yield predictable results is an exemplary rationale for a prima facie case of obviousness. MPEP2143. It would have been prima facie obvious to combine Morano, Huxley, and Patnaik’s methods for a method measuring CTLA4 reducing B7-1 binding to CD28. Furthermore, to measure measuring synaptic puncta density of neurons that express p75 neurotrophin receptor, because levels can increase in the presence of disease. In regard to claim 11, Patnaik et al teaches detecting p75 neurotrophin receptor on dendritic spine on hippocampal neurons [Abstract]. In regard to claim 13, Huxley et al teaches using blocking agents to treat inflammatory disease [Summary]. In regard to claims 14 and 17, Huxley et al teaches using CTLA-4Ig for multiple sclerosis [Right column, 2nd paragraph, pg. 1651]. Applicant’s Arguments: Applicant respectfully traverses this rejection. Morano is a brief abstract reporting only a qualitative observation of competition between native ligands (CTLA- 4 and NGFR) for B7-1, and it expressly states that the "structure and function of the B7-1-NGFR interaction is currently unknown." A person of ordinary skill in the art would have had no motivation to establish a quantitative screening and selection method for exogenous test agents, because the functional significance of the B7-1:p75NTR interaction in the nervous system was completely unresolved. Moreover, a person of ordinary skill in the art would have had no reasonable expectation of success in identifying or selecting functional B7-1 blocking agents using a quantitative threshold, for the same reason Brennan does not disclose p75NTR or its interaction with B7-1. Morano lacks any quantitative selection, and Brennan fails to address p75NTR; Morano reports only a qualitative observation that native CTLA-4 and NGFR (p75NTR) compete for B7-1 binding. As to claim 9, the Examiner's assertion that Huxley's Compound 1 "does not significantly reduce B7-1 binding to CD28" is factually incorrect. The Examiner has not articulated any reason why a person of ordinary skill would substitute B7-1 for A31-42 in Patnaik's assay system, nor why a "B7-1-specific blocking agent," as identified through the CD28/CTLA-4 selectivity screen of claims 8-9, would be expected to have any effect on an A3-driven p75NTR pathology model. Amyloid-3 and B7-1 are structurally and functionally unrelated proteins that Patnaik does not suggest engage p75NTR through a common or interchangeable mechanism. Examiner’s Response: Applicant states, “A person of ordinary skill in the art would have had no motivation to establish a quantitative screening and selection method for exogenous test agents, because the functional significance of the B7-1:p75NTR interaction in the nervous system was completely unresolved”. Claim 1 is directed to a method comprising incubating one or more test agents with B7-1 and p75 neurotrophin receptor, measuring any reduction in B7-1:p75 neurotrophin receptor binding when compared to a control assay. Morano teaches CTLA “a test agent” decreased p75 neurotrophin receptor binding with B7-1, because Morano teaches p75 neurotrophin and CTLA compete for binding to B7-1. The functional significance of the B7-1:p75NTR interaction in the nervous system is not a claim limitation. Applicant states, “Brennan does not disclose p75NTR or its interaction with B7-1”. Morano et al teaches CTLA “a test agent” decreased p75 neurotrophin receptor binding with B7-1, because Morano teaches p75 neurotrophin and CTLA compete for binding to B7-1. One of ordinary skill would recognize Morano’s method of reducing B7-1:p75NTR binding comprising CTLA4 addresses p75NTR interaction with B7-1. Applicant states, “the Examiner's assertion that Huxley's Compound 1 "does not significantly reduce B7-1 binding to CD28" is factually incorrect.”. Examiner agrees, Figure 2 shows reductions in CTLA-4 to B7-1. Applicant states, “why a person of ordinary skill would substitute B7-1 for A31-42 in Patnaik's assay system, nor why a "B7-1-specific blocking agent," as identified through the CD28/CTLA-4 selectivity screen of claims 8-9, would be expected to have any effect on an A3-driven p75NTR pathology model. Amyloid-3 and B7-1 are structurally and functionally unrelated proteins that Patnaik does not suggest engage p75NTR”. One of ordinary skill would have been motivated to substitute B7-1 for A31-42, because Patnaik teaches a method of incubating oligomers that bind p75NTR and block the binding of B7-1 to p75NTR. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to DENNIS JOHN SULLIVAN whose telephone number is (571)272-0509. The examiner can normally be reached Mon - Fri: 7:30AM - 4:30PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Samira Jean-Louis can be reached at (571) 270-3503. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /DENNIS J SULLIVAN/Examiner, Art Unit 1642 /NELSON B MOSELEY II/Primary Examiner, Art Unit 1642
Read full office action

Prosecution Timeline

Oct 20, 2023
Application Filed
Oct 20, 2023
Response after Non-Final Action
May 15, 2026
Non-Final Rejection mailed — §102, §103
Aug 24, 2026
Response Filed
Nov 05, 2026
Final Rejection mailed — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12780948
BISPECIFIC BINDING AGENTS AND USES THEREOF
6y 1m to grant Granted Nov 03, 2026
Patent 12780940
PROTEIN COMPRISING ANTIBODY FOR TARGETING ONCOGENIC PROTEIN OR SINGLE CHAIN FRAGMENT VARIABLE THEREOF AND CANCER CELL PENETRATING PEPTIDE, AND USE OF THE SAME
3y 9m to grant Granted Nov 03, 2026
Patent 12728163
INTRACELLULAR DELIVERY OF BIOMOLECULES TO MODIFY IMMUNE RESPONSE
5y 12m to grant Granted Sep 08, 2026
Patent 12693289
APPLICATION OF COMPOUNDS IN THE PREPARATION OF REAGENTS FOR DOWN-REGULATION OF RUNX2
3y 2m to grant Granted Jul 28, 2026
Patent 12674796
SINGLE CELL PATHOLOGY ANALYSIS OF TUMOUR SAMPLES
3y 11m to grant Granted Jul 07, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
58%
Grant Probability
99%
With Interview (+48.3%)
3y 8m (~7m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 119 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month